These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33860898)

  • 1. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study.
    Kang SH; Lee M; Kim MY; Lee JH; Jun BG; Kim TS; Choi DH; Suk KT; Kim YD; Cheon GJ; Kim DJ; Baik SK
    Hepatol Int; 2021 Apr; 15(2):424-436. PubMed ID: 33860898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
    Paternostro R; Becker J; Hofer BS; Panagl V; Schiffke H; Simbrunner B; Semmler G; Schwabl P; Scheiner B; Bucsics T; Bauer D; Binter T; Trauner M; Mandorfer M; Reiberger T
    Dig Liver Dis; 2022 Apr; 54(4):500-508. PubMed ID: 34799282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
    Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
    J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding.
    Pfisterer N; Dexheimer C; Fuchs EM; Bucsics T; Schwabl P; Mandorfer M; Gessl I; Sandrieser L; Baumann L; Riedl F; Scheiner B; Pachofszky T; Dolak W; Schrutka-Kölbl C; Ferlitsch A; Schöniger-Hekele M; Peck-Radosavljevic M; Trauner M; Madl C; Reiberger T
    Aliment Pharmacol Ther; 2018 Apr; 47(7):966-979. PubMed ID: 29388229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
    Gillespie SL; Hanrahan TP; Rockey DC; Majumdar A; Hayes PC
    Aliment Pharmacol Ther; 2023 Mar; 57(5):454-463. PubMed ID: 36691947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-blockers on multiple haemodynamics in cirrhosis: A cross-over study by MR-imaging and hepatic vein catheterization.
    Danielsen KV; Nabilou P; Wiese SS; Hove JD; Bendtsen F; Møller S
    Liver Int; 2023 Oct; 43(10):2245-2255. PubMed ID: 37387503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?
    Burza MA; Marschall HU; Napoleone L; Molinaro A
    Pharmacol Res; 2017 May; 119():20-26. PubMed ID: 28099882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers.
    Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F
    Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.
    Scheiner B; Parada-Rodriguez D; Bucsics T; Schwabl P; Mandorfer M; Pfisterer N; Riedl F; Sieghart W; Ferlitsch A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Scand J Gastroenterol; 2017 Sep; 52(9):1008-1015. PubMed ID: 28532189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J; Iwakiri Y
    Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis.
    Kim BH; Chung JW; Lee CS; Jang ES; Jeong SH; Kim N; Kim JW
    Korean J Intern Med; 2019 Nov; 34(6):1233-1243. PubMed ID: 30759966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis.
    Zaghloul SG; Wahab EA; Seleem WM; Hanafy AS; Gomaa AF; Lakouz K; Amin AI
    Drug Discov Ther; 2019; 13(2):108-113. PubMed ID: 31080201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
    Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Nonselective β-Blockers on Mortality in Patients With End-Stage Cirrhosis.
    Snoga JL; Lusk KA; Attridge RT; Attridge RL
    Ann Pharmacother; 2020 Apr; 54(4):322-330. PubMed ID: 31701773
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemodynamic Response to Carvedilol is Maintained for Long Periods and Leads to Better Clinical Outcome in Cirrhosis: A Prospective Study.
    Kirnake V; Arora A; Gupta V; Sharma P; Singla V; Bansal N; Goyal M; Chawlani R; Kumar A
    J Clin Exp Hepatol; 2016 Sep; 6(3):175-185. PubMed ID: 27746613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers.
    Giannitrapani L; Granà W; Licata A; Schiavone C; Montalto G; Soresi M
    Med Princ Pract; 2018; 27(5):466-471. PubMed ID: 30107378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients.
    Marasco G; Dajti E; Ravaioli F; Alemanni LV; Capuano F; Gjini K; Colecchia L; Puppini G; Cusumano C; Renzulli M; Golfieri R; Festi D; Colecchia A
    Hepatol Int; 2020 Sep; 14(5):850-857. PubMed ID: 32557193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meta-analysis of β-blockers for the primary prevention of liver cirrhosis with clinically significant portal hypertension with no or small esophageal varices].
    Su X; Li WJ; Chen Z; Wu QB; Yin MH; Han X; Zhang DP; Zhou XQ; Zhu H
    Zhonghua Gan Zang Bing Za Zhi; 2022 Nov; 30(11):1237-1245. PubMed ID: 36891704
    [No Abstract]   [Full Text] [Related]  

  • 19. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.
    Turco L; Villanueva C; La Mura V; García-Pagán JC; Reiberger T; Genescà J; Groszmann RJ; Sharma BC; Merkel C; Bureau C; Alvarado E; Abraldes JG; Albillos A; Bañares R; Peck-Radosavljevic M; Augustin S; Sarin SK; Bosch J; García-Tsao G
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):313-327.e6. PubMed ID: 31176013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis.
    Danielsen KV; Hove JD; Nabilou P; Yin M; Chen J; Zhao M; Kallemose T; Teisner AS; Siebner HR; Ehman RL; Møller S; Bendtsen F
    Liver Int; 2021 Sep; 41(9):2149-2158. PubMed ID: 34060714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.